Forus pitches a nationwide network spanning the medicine lifecycle

Forus says its network is designed to support biopharma companies beyond AI-based molecule discovery, covering clinical-trial site selection and patient recruitment, launch planning, physician targeting, coverage, distribution, and post-market monitoring. The company says turning a molecule into an approved medicine can still take more than a decade and billions of dollars.

Forus says its platform is gaining nationwide visibility into medicine performance and the clinical and practice behavior of patients and physicians. As an example, it claims that 40% of people who had ever taken a new autoimmune-disease drug launched in March came through the platform.

The company characterizes this level of visibility as unprecedented and says it could make drug development and commercialization faster, more efficient, and more predictable. Its stated goal is to increase the number of medicines reaching the market each year by an order of magnitude.